Go to the list of all blogs
Allana's Avatar
published in Blogs
Aug 30, 2020
3 Predictions of Where the Dow Jones Industrial Average Will Finish in 2019 (and Why They'll All Probably Be Wrong)

3 Predictions of Where the Dow Jones Industrial Average Will Finish in 2019 (and Why They'll All Probably Be Wrong)

One reason why so many people are fascinated by the stock market is that it's inherently unpredictable. No matter how well a company seems to be doing, an unexpected shock can send its stock price plummeting. And regardless of how sure you might be that a beaten-down company will simply fade away, a turnaround strategy can lead to a huge rebound in its stock price.

READ MORE...

Related Ticker: RYDAX

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Notable companies

The most notable companies in this group are Alphabet (NASDAQ:GOOGL), Microsoft Corp (NASDAQ:MSFT), VISA (NYSE:V), Caterpillar (NYSE:CAT), Unitedhealth Group (NYSE:UNH), Home Depot (NYSE:HD), Goldman Sachs Group (NYSE:GS), American Express Company (NYSE:AXP), Amgen (NASDAQ:AMGN).

Industry description

The investment seeks to provide investment results that match, before fees and expenses, the performance of the Dow Jones Industrial Average® on a daily basis. The fund will invest at least 80% of its net assets, plus any borrowings for investment purposes, in securities of companies in the underlying index and derivatives and other instruments whose performance is expected to correspond to that of the underlying index. The Dow Jones Industrial Average ® is a price-weighted index of 30 "blue chip" U.S. stocks. The fund is non-diversified.

Market Cap

The average market capitalization across the Rydex Dow Jones Industrial Average® A MF is 831.54B. The market cap for tickers in the group ranges from 79.16B to 4.12T. GOOGL holds the highest valuation in this group at 4.12T. The lowest valued company is SHW at 79.16B.

Volume

The average weekly volume growth across all stocks in the Rydex Dow Jones Industrial Average® A MF was 3%. For the same stocks of the MF, the average monthly volume growth was 8% and the average quarterly volume growth was -40%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 55
Price Growth Rating: 43
SMR Rating: 27
Profit Risk Rating: 43
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category LargeValue

Profile
Details
Category
Large Value
Address
Rydex Series Funds9601 Blackwell Road,Suite 500Rockville
Phone
N/A
Web
www.rydex-sgi.com
Interact to see
Advertisement
What if a single trading robot could harvest volatility across semiconductors, oil, and communication technology — simultaneously — while filtering out the noise that burns most active traders? That's exactly what the Semiconductors, Oil & Energy, Communication Tech AI Trading Agent delivers. Over the past 364 days (March 5, 2025 – March 4, 2026), this agent generated a Total Net Profit of $20,641.78 on $500-per-trade sizing — an eye-catching Annualized Return of 68.58%. With 1,534 closed trades, a 61.86% win rate, and a dominant Profit Factor of 3.02
What if an AI trading agent could turn market chaos into a 45.55% annualized return? That's exactly what Tickeron's HUBB, AVGO, ITA, QQQ – AI Trading Agent (4 Tickers, 5min) has delivered across 106 days of live trading — posting $11,605.87 in total net profit from a per-trade allocation of $2,500–$8,250, a 69.59% win rate across 444 closed trades, and a Profit Factor of 2.18.
83.97% Win Rate | 87.10% Annualized Return | $44,879.15 Total Net Profit | Profit Factor: 4.92 | Sharpe Ratio: 1.13
HYMC’s latest sell‑off is part of a broader downtrend that accelerated after the company delayed its PEA, which investors interpreted as an uncertainty event despite no immediate change in reported resources or cash position. Technical indicators such as HYMC breaking above its upper Bollinger Band and then rolling over, along with the Aroon indicator turning down in late February, signaled an elevated risk of a sharp pullback that is now playing out.
DSGR reported quarterly EPS of about 0.18 dollars, badly missing consensus estimates of roughly 0.32–0.33 dollars per share and marking a sharp drop from 0.42 dollars a year ago, which triggered a large negative earnings surprise. Revenue of about 481–482 million dollars came in below expectations near 496 million dollars, and adjusted EBITDA margins compressed to about 7.4% from 9.3% in the prior‑year quarter, highlighting cost and mix pressures.
Shares of CRDO surged +11.90% on March 5, 2026, closing at $114.74 versus a prior close of $102.54. Primary catalyst: Strong Q3 fiscal 2026 earnings reported on March 2, with revenue of $407 million beating consensus estimates by more than $19 million and non-GAAP EPS of $1.07 surpassing forecasts by $0.29.
SPY is trading down approximately -1.30% in Friday premarket, slipping from the prior session's close of $681.31 to around $677–$678. The primary catalyst is a sharply negative February 2026 Nonfarm Payrolls report, which showed a decline of 92,000 jobs — a massive miss versus the consensus forecast of +50,000.
WAL shares dropped approximately 12% in early trading on March 6, 2026, from a prior close of ~$80.74 to roughly ~$71, marking one of the stock's sharpest single-session declines in recent months. The primary catalyst was a surprise announcement that Jefferies Financial Group declined to make a $126.4 million payment owed to Western Alliance Bank under a forbearance agreement tied to the LAM Trade Finance loan portfolio.
MRVL shares surged approximately +15% at the open on March 6, 2026, after closing at $75.68 the prior session. The primary catalyst was a strong Q4 fiscal 2026 earnings report released after the close on March 5, with non-GAAP EPS of $0.80 beating the $0.79 consensus estimate and revenue of $2.219 billion exceeding expectations.
Shares of Day One Biopharmaceuticals surged approximately +65.57% on March 6, 2026, rising from a prior close of $12.78 to an intraday price around $21.16. The primary catalyst driving the session's gains is acquisition and takeover speculation, with reports circulating that Day One may be a buyout target.
GAP shares fell approximately 13% in early trading on March 6, 2026, following the company's Q4 fiscal 2025 earnings report released after market close on March 5. Gap met Wall Street's Q4 estimates on both earnings per share and revenue, but fiscal 2026 guidance fell short of analyst expectations.
Shares of Red Cat Holdings surged approximately +22% in early Friday trading on March 6, 2026, building on a powerful week of momentum in defense drone stocks. The primary catalyst is escalating geopolitical conflict — U.S. and Israeli military strikes on Iran, which dramatically boosted investor appetite for domestic drone and defense technology companies.
The primary catalyst for the decline was the pricing of a secondary offering of roughly 9 million shares at about 22.25 dollars per share by Ingram Holdco, an affiliate of Platinum Equity, with all proceeds going to the selling shareholder and not to Ingram Micro itself. Investors often view such secondary offerings as short‑term bearish because they increase the freely tradable float and signal that a major holder is cashing out part of its stake, even if the company’s operations remain intact.
Rumble reported Q4 2025 revenue of about 27.1 million dollars, below consensus expectations near 29 million dollars and down roughly 10% year over year, confirming that top‑line momentum has stalled. GAAP EPS came in at a loss of around 0.13 dollars, missing analyst estimates by roughly 0.05 dollars and underscoring that the platform remains far from break‑even despite prior cost cuts and efficiency efforts.
Tronox’s Q4 2025 non‑GAAP EPS came in at a loss of about 0.60 dollars, missing expectations by roughly 0.02 dollars, while revenue of around 730 million dollars grew about 8% year over year, showing volume resilience but weak earnings power.
Defense budgets worldwide are surging — global military spending topped $2.2 trillion in 2023, a record high — while semiconductor demand is projected to reach a $1 trillion industry by 2030. At the intersection of these two mega-trends sits one of Tickeron's most strategically focused AI Trading Robots: the XAR, ITA, SOXL – AI Trading Agent (3 Tickers), 15min.
HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.
XENE shares surged approximately +45.93% in premarket trading on March 9, 2026, one of the largest single-session moves in the company's history. The primary catalyst: Xenon announced positive topline Phase 3 X-TOLE2 results for its lead drug candidate azetukalner in focal onset seizures (FOS), meeting the primary endpoint with overwhelming statistical significance.
Shares of OLMA dropped approximately 41% in Monday's session, one of the steepest single-day declines in the company's history. The primary catalyst was Roche's Phase 3 persevERA trial failure — a late-stage study of giredestrant, a closely competing selective estrogen receptor degrader (SERD), which missed its primary endpoint of statistically significant improvement in progression-free survival.
RLMD shares surged approximately +40% at the open on March 9, 2026, rising from a prior close of $4.45 to approximately $6.23, driven by a major clinical trial readout. The primary catalyst was the announcement of 12-month interim data from the Phase 2 trial of NDV-01, Relmada's lead oncology candidate, in patients with high-risk non-muscle invasive bladder cancer (NMIBC) — results that significantly exceeded historical benchmarks.